HCPCS Level II drug code
J3357 — Injection, ustekinumab, for subcutaneous injection, 1 mg
In short
J3357 is the HCPCS Level II code for injection, ustekinumab, for subcutaneous injection, 1 mg. One billing unit is 1 mg.
Code
Med-Code curatedHCPCS codeJ3357
Billing unit1 mg
- Descriptor
- Injection, ustekinumab, for subcutaneous injection, 1 mg
- Code set
- HCPCS Level II, maintained by CMS
- Category
- Immunology / IL-12/23
Units and claim line
Units = dose given ÷ 1 mg. For example, 100 mg is 100 units. Enter the dose to get the units and the NDC line for the CMS-1500 and the 837P.
Enter the dose given to build the claim line.
Drugs mapped to J3357
- StelaraBrandJ3357 covers the subcutaneous formulation. The intravenous formulation has a separate code (J3358). Ustekinumab biosimilars are listed under their own names.
- UstekinumabGenericJ3357 covers the subcutaneous formulation. The intravenous formulation has a separate code (J3358). Ustekinumab biosimilars are listed under their own names.
FDA-listed products billed under J3357
Finished products in the FDA NDC Directory whose brand or single active ingredient, and route, match this code’s entry.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Pyzchivaustekinumab-ttwe | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-651 |
| Pyzchivaustekinumab-ttwe | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-652 |
| Selarsdiustekinumab-aekn | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | A-S Medication Solutions | 50090-7769 |
| Steqeymaustekinumab-stba | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | CELLTRION USA, Inc. | 72606-027 |
| Steqeymaustekinumab-stba | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | CELLTRION USA, Inc. | 72606-028 |
| Steqeymaustekinumab-stba | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | CELLTRION USA, Inc. | 72606-060 |
| Stelaraustekinumab | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Janssen Biotech, Inc. | 57894-060 |
| Stelaraustekinumab | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | Janssen Biotech, Inc. | 57894-061 |
| ustekinumab | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Janssen Biotech, Inc. | 57894-440 |
| ustekinumab | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | Janssen Biotech, Inc. | 57894-441 |
| Starjemzaustekinumab-hmny | Ustekinumab 45 mg/.5mL | InjectionSubcutaneous | Hikma Pharmaceuticals USA Inc. | 0143-9168 |
| Ustekinumab-Ttwe | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Quallent Pharmaceuticals Health LLC | 82009-160 |
| Ustekinumab-Ttwe | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Quallent Pharmaceuticals Health LLC | 82009-161 |
| Ustekinumab-Ttwe | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | Quallent Pharmaceuticals Health LLC | 82009-162 |
| Starjemzaustekinumab-hmny | Ustekinumab 45 mg/.5mL | InjectionSubcutaneous | Hikma Pharmaceuticals USA Inc. | 0143-9169 |
| Wezlanaustekinumab-auub | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Nuvaila Limited | 84612-055 |
| Wezlanaustekinumab-auub | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Nuvaila Limited | 84612-076 |
| Wezlanaustekinumab-auub | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | Nuvaila Limited | 84612-089 |
| Starjemzaustekinumab-hmny | Ustekinumab 90 mg/mL | InjectionSubcutaneous | Hikma Pharmaceuticals USA Inc. | 0143-9170 |
| Wezlanaustekinumab-auub | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Nuvaila Limited | 84612-855 |
| Wezlanaustekinumab-auub | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Nuvaila Limited | 84612-876 |
| Wezlanaustekinumab-auub | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | Nuvaila Limited | 84612-889 |
| Otulfiustekinumab-aauz | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Fresenius Kabi USA, LLC | 65219-822 |
| Otulfiustekinumab-aauz | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | Fresenius Kabi USA, LLC | 65219-824 |
| Otulfiustekinumab-aauz | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | Fresenius Kabi USA, LLC | 65219-826 |
All NDCs for these drugs
- Pyzchiva NDC codesDrug page
- Selarsdi NDC codesDrug page
- Steqeyma NDC codesDrug page
- Stelara NDC codesDrug page
- ustekinumab NDC codesDrug page
- Starjemza NDC codesDrug page
- Ustekinumab-Ttwe NDC codesDrug page
- Wezlana NDC codesDrug page
- Otulfi NDC codesDrug page
- Ustekinumab-Aauz NDC codesDrug page
- Yesintek NDC codesDrug page
- Products containing UstekinumabActive ingredient page
J3357: common questions
- Is J3357 a CPT code?
- No. J3357 is a HCPCS Level II code, maintained by CMS, that identifies the drug supplied. CPT codes are five-digit numbers from the AMA that describe services. Giving the drug, for example an injection or infusion, is usually reported with a separate CPT administration code. CPT codes for drug administration.
- What is one billing unit of J3357?
- One unit of J3357 is 1 mg, as stated in the code's descriptor. Units to report = dose given ÷ 1 mg. J-code billing units.